Anchor Capital Advisors LLC trimmed its stake in shares of Amdocs Limited (NASDAQ:DOX) by 1.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 417,218 shares of the technology company’s stock after selling 4,214 shares during the quarter. Anchor Capital Advisors LLC owned about 0.29% of Amdocs worth $27,837,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Delpha Capital Management LLC bought a new position in Amdocs during the fourth quarter worth $109,000. Focused Wealth Management Inc bought a new position in Amdocs during the fourth quarter worth $157,000. American International Group Inc. bought a new position in Amdocs during the fourth quarter worth $199,000. CENTRAL TRUST Co boosted its position in Amdocs by 45.0% during the fourth quarter. CENTRAL TRUST Co now owns 3,388 shares of the technology company’s stock worth $222,000 after purchasing an additional 1,052 shares during the period. Finally, Cerebellum GP LLC bought a new position in Amdocs during the fourth quarter worth $246,000. 92.35% of the stock is owned by hedge funds and other institutional investors.
DOX has been the subject of a number of research reports. Jefferies Group raised Amdocs from a “hold” rating to a “buy” rating and dropped their target price for the stock from $71.37 to $60.20 in a report on Monday, March 19th. ValuEngine raised Amdocs from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Oppenheimer reissued a “buy” rating and set a $77.00 target price on shares of Amdocs in a report on Wednesday, January 31st. Stifel Nicolaus lifted their target price on Amdocs from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Zacks Investment Research raised Amdocs from a “hold” rating to a “buy” rating and set a $74.00 target price for the company in a report on Tuesday, April 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. Amdocs currently has an average rating of “Hold” and an average target price of $70.03.
DOX opened at $65.44 on Tuesday. Amdocs Limited has a fifty-two week low of $61.00 and a fifty-two week high of $71.72. The firm has a market cap of $9.37 billion, a PE ratio of 18.43, a PEG ratio of 2.20 and a beta of 0.55.
Amdocs (NASDAQ:DOX) last posted its quarterly earnings results on Thursday, May 10th. The technology company reported $0.95 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.95. The business had revenue of $992.34 million during the quarter, compared to the consensus estimate of $980.59 million. Amdocs had a return on equity of 15.07% and a net margin of 11.36%. Amdocs’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.94 earnings per share. research analysts forecast that Amdocs Limited will post 3.8 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 20th. Investors of record on Friday, June 29th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date is Thursday, June 28th. Amdocs’s dividend payout ratio (DPR) is presently 28.17%.
Amdocs Company Profile
Amdocs Limited, through its subsidiaries, provides software and services solutions to the communications, entertainment, pay TV, and media industry service providers worldwide. The company offers customer experience and monetization solutions that allow its customers to contextual and personalize interactions.
Want to see what other hedge funds are holding DOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amdocs Limited (NASDAQ:DOX).
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.